[Phase 1 of clinical trial: The issue of dose-escalating].
SIRIC OncoLille Consortium, Clinical Research and Methodology Platform, 59037 Lille, France. Electronic address: n-penel@o-lambret.fr.
Nicolas
N
Penel
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans
D000970:Antineoplastic Agents